Head to Head Review: Organovo Holdings (ONVO) & Mesoblast Limited (MESO)
Organovo Holdings (NASDAQ: ONVO) and Mesoblast Limited (NASDAQ:MESO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.
Valuation and Earnings
This table compares Organovo Holdings and Mesoblast Limited’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Mesoblast Limited||$2.41 million||212.00||-$87.03 million||($0.96)||-6.13|
Organovo Holdings has higher revenue, but lower earnings than Mesoblast Limited. Mesoblast Limited is trading at a lower price-to-earnings ratio than Organovo Holdings, indicating that it is currently the more affordable of the two stocks.
This is a summary of current ratings for Organovo Holdings and Mesoblast Limited, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Organovo Holdings presently has a consensus price target of $6.94, indicating a potential upside of 219.70%. Mesoblast Limited has a consensus price target of $14.25, indicating a potential upside of 142.23%. Given Organovo Holdings’ stronger consensus rating and higher possible upside, analysts clearly believe Organovo Holdings is more favorable than Mesoblast Limited.
This table compares Organovo Holdings and Mesoblast Limited’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Organovo Holdings has a beta of 2.98, meaning that its share price is 198% more volatile than the S&P 500. Comparatively, Mesoblast Limited has a beta of 2.78, meaning that its share price is 178% more volatile than the S&P 500.
Institutional and Insider Ownership
23.9% of Organovo Holdings shares are owned by institutional investors. Comparatively, 3.0% of Mesoblast Limited shares are owned by institutional investors. 10.2% of Organovo Holdings shares are owned by company insiders. Comparatively, 18.8% of Mesoblast Limited shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Organovo Holdings beats Mesoblast Limited on 6 of the 10 factors compared between the two stocks.
Organovo Holdings Company Profile
Organovo Holdings, Inc. is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products, including 3D human tissues used for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (ADME), and drug metabolism and pharmacokinetics (DMPK); customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development, and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair and functional tissue patches for the repair or replacement of damaged tissues and organs.
Mesoblast Limited Company Profile
Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.
Receive News & Stock Ratings for Organovo Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo Holdings Inc. and related stocks with our FREE daily email newsletter.